Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT03589469. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
Study identification
- NCT ID
- NCT03589469
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 145 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2018 (Actual)
- Primary completion
- May 24, 2020 (Actual)
- Completion
- Aug 9, 2022 (Actual)
- Last update posted
- Aug 29, 2023
2018 – 2022
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| Compassionate Care Research Group, Inc., at Compassionate Care Medical Group, Inc. | Fountain Valley | California | 92708 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California, San Francisco Medical Center | San Francisco | California | 94143 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90602 | — |
| University of Miami Hospital and Clinics | Miami | Florida | 33136 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Northwest Georgia Oncology Centers, PC-Drug Shipment, Lab and Study Supplies Only | Marietta | Georgia | 30060 | — |
| Medical Oncology & Hematology Associates | Des Moines | Iowa | 50309 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center/ Nebraska Medicine | Omaha | Nebraska | 68198 | — |
| North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists | East Setauket | New York | 11733 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| GHD Cancer Institute | Greenville | South Carolina | 29605 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Baylor Scott & White Medical Center - Temple | Temple | Texas | 76508 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Vista Oncology Inc. PS | Olympia | Washington | 98506 | — |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03589469, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 29, 2023 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03589469 live on ClinicalTrials.gov.